Vanguard Group Inc ownership in LGDN / Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

DE ˙ DB ˙ US53220K5048

€198,00 ↑2,00 (1,02%)

2026-06-04
HİSSE FİYATI

Security	DE:LGDN / Ligand Pharmaceuticals Incorporated
Institution	Vanguard Group Inc
Latest Disclosed Ownership	1,876,514 shares
Ownership	10.76%

2024-02-13 - Vanguard Group Inc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 1,876,514 shares of Ligand Pharmaceuticals Incorporated (DE:LGDN). This represents 10.76 percent ownership of the company. In their previous filing dated 2023-02-09 , Vanguard Group Inc had reported owning 1,843,115 shares, indicating an increase of 1.81 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2024-02-13	2024-02-13	13G/A	1,843,115	1,876,514	1.81	10.76	-1.37
2023-02-09	2023-02-09	13G/A	1,716,735	1,843,115	7.36	10.91	6.23
2022-02-10	2022-02-10	13G/A	1,722,291	1,716,735	-0.32	10.27	-0.58
2021-10-12	2021-10-12	13G/A	1,458,925	1,722,291	18.05	10.33	13.89
2021-02-10	2021-02-10	13G/A	1,570,013	1,458,925	-7.08	9.07	1.57
2020-02-12	2020-02-12	13G/A	1,929,850	1,570,013	-18.65	8.93	-1.54
2019-02-12	2019-02-12	13G/A	1,847,814	1,929,850	4.44	9.07	3.66
2018-02-09	2018-02-09	13G/A	1,613,425	1,847,814	14.53	8.75	13.49
2017-02-10	2017-02-10	13G/A	1,348,453	1,613,425	19.65	7.71	14.05
2016-02-10	2016-02-10	13G/A		1,348,453		6.76
2015-02-10	2015-02-10	13G		997,254		5.07
2014-02-12	2014-02-12	13G/A		680,017		3.33
2013-02-13	2013-02-13	13G		1,062,525		5.32
2012-02-09	2012-02-09	13G/A		975,048		4.96

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-01-29	2025-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,073,892	-2,391	-0.12	392,111	6.61	0.0057
2025-11-07	2025-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,076,283	-13,088	-0.63	367,793	54.85	0.0055
2025-08-11	2025-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,089,371	33,639	1.64	237,520	9.89	0.0038
2025-05-09	2025-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,055,732	-29,895	-1.43	216,140	-3.28	0.0039
2025-02-11	2024-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,085,627	115,005	5.84	223,475	13.30	0.0039
2024-11-13	2024-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,970,622	43,748	2.27	197,240	21.48	0.0035
2024-08-13	2024-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,926,874	42,762	2.27	162,358	17.88	0.0031
2024-05-10	2024-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,884,112	7,598	0.40	137,729	2.77	0.0027
2024-03-11	2023-12-31	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,876,514	24,653	1.33	134,021	20.78	0.0029
2024-02-14	2023-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,876,514	24,653		134,021		0.0025
2023-12-18	2023-09-30	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,851,861	-1,492	-0.08	110,964	-16.96	0.0027
2023-11-14	2023-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,851,861	-1,492		110,964		0.0005
2023-08-14	2023-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,853,353	-5,261	-0.28	133,627	-2.26	0.0032
2023-07-14	2023-03-31	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,858,614	15,499	0.84	136,720	11.05	0.0035
2023-05-15	2023-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,858,614	15,499		136,720		0.0007
2023-02-10	2022-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,843,115	49,701	2.77	123,120	-20.28	0.0034
2022-11-14	2022-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,793,414	19,440	1.10	154,432	-2.43	0.0045
2022-08-12	2022-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,773,974	46,336	2.68	158,274	-18.56	0.0044
2022-05-13	2022-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,727,638	10,903	0.64	194,342	-26.71	0.0046
2022-02-14	2021-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,716,735	-5,556	-0.32	265,166	10.51	0.0060
2021-11-12	2021-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,722,291	198,136	13.00	239,949	20.00	0.0060
2021-08-13	2021-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,524,155	5,913	0.39	199,954	-13.61	0.0050
2021-05-14	2021-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,518,242	59,317	4.07	231,455	59.53	0.0063
2021-02-12	2020-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,458,925	29,632	2.07	145,090	6.50	0.0042
2020-11-16	2020-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,429,293	-57,310	-3.86	136,239	-18.07	0.0045
2020-08-14	2020-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,486,603	-107,347	-6.73	166,277	43.45	0.0059
2020-05-15	2020-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,593,950	23,937	1.52	115,912	-29.21	0.0049
2020-02-14	2019-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,570,013	-72,049	-4.39	163,736	0.17	0.0056
2019-11-14	2019-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,642,062	-68,959	-4.03	163,450	-16.31	0.0061
2019-08-14	2019-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,711,021	-221,175	-11.45	195,313	-19.59	0.0073
2019-05-15	2019-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,932,196	2,346	0.12	242,896	-7.25	0.0095
2019-02-14	2018-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,929,850	-160,287	-7.67	261,881	-54.35	0.0118
2018-12-13	2018-09-30	13F/A-2	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,090,137	66,789	3.30	573,721	36.87	0.0224
2018-11-23	2018-09-30	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,090,137	0		573,721		0.0224
2018-11-14	2018-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,090,137	66,789		573,721
2018-08-14	2018-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	2,023,348	81,606	4.20	419,177	30.71	0.0175
2018-05-15	2018-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,941,742	93,928	5.08	320,699	26.75	0.0140
2018-02-14	2017-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,847,814	75,236	4.24	253,021	4.84	0.0111
2017-11-14	2017-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,772,578	30,760	1.77	241,337	14.13	0.0113
2017-08-24	2017-06-30	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,741,818	54,200	3.21	211,457	18.39	0.0104
2017-08-11	2017-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,741,818	54,200		211,457
2017-05-12	2017-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,687,618	74,193	4.60	178,618	8.95	0.0092
2017-02-14	2016-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,613,425	54,085	3.47	163,940	3.01	0.0091
2016-11-14	2016-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,559,340	43,526	2.87	159,147	-11.97	0.0093
2016-08-10	2016-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,515,814	111,807	7.96	180,790	20.24	0.0112
2016-05-13	2016-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,404,007	55,554	4.12	150,355	2.84	0.0097
2016-02-08	2015-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,348,453	15,436	1.16	146,199	28.05	0.0098
2015-11-12	2015-09-30	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,333,017	21,254	1.62	114,173	-13.74	0.0048
2015-11-12	2015-09-30	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,333,017	21,254		114,173		0.0048
2015-08-13	2015-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,311,763	294,892	29.00	132,357	68.80	0.0089
2015-05-15	2015-03-31	13F/A-1	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,016,871	19,617	1.97	78,411	47.77	0.0053
2015-05-14	2015-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,016,871			78,411
2015-02-12	2014-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	997,254	77,254	8.40	53,064	22.75	0.0038
2014-11-12	2014-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	920,000	-123,782	-11.86	43,230	-33.51	0.0034
2014-08-11	2014-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	1,043,782	59,543	6.05	65,017	-1.79	0.0051
2014-05-13	2014-03-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	984,239	304,222	44.74	66,200	85.08	0.0056
2014-02-12	2013-12-31	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	680,017	127,408	23.06	35,769	49.55	0.0031
2013-11-07	2013-09-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	552,609	9,524	1.75	23,917	17.69	0.0023
2013-08-13	2013-06-30	13F	LIGAND PHARMACEUTICALS	COM NEW	53220K504	543,085	543,085		20,322		0.0021

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.